Cytocom, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cytocom Inc. (NASDAQ: CBLI) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary Advanced Immunomodulating Multi-receptor System (AIMS) platform designed to rebalance the body's immune system and restore homeostasis; core products and programs include noroxymorphone analogs and proenkephalin analogs multi-receptor modulating therapies, CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis and COVID-19, CYTO-400 for hepatocellular and pancreatic cancer, CYTO-600 and entolimod for acute radiation syndrome, advanced solid tumors and vaccine adjuvant, as well as toll-like receptor (TLR4, TLR5, TLR9) agonists addressing radiation injury, immuno-oncology and side effects from cancer treatments. The company, founded prior to its 2021 merger with Cleveland BioLabs Inc. and headquartered in Fort Collins, Colorado, operates primarily in the United States with a focus on clinical-stage programs for gastrointestinal, oncology and autoimmune markets. In recent developments, Cytocom completed its all-stock merger with Cleveland BioLabs in July 2021 to enhance its immunotherapy platforms and pipeline, acquired ImQuest Life Sciences to bolster development valued at $12 million, secured up to $90 million in committed capital including a $75 million equity line from GEM Global Yield LLC, established a multi-year collaboration with the La Jolla Institute for Immunology funding up to $1.4 million annually for toll-like receptor research in cancer, infectious and autoimmune diseases, and listed its common shares on Nasdaq under CBLI following the merger.
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
Cytocom, Inc. Reports Second Quarter 2021 Financial Results
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened
Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC
Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532
SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations
CBLI Stock Price Increases Over 60% Pre-Market: Why It Happened
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - CBLI, IPHI, CBMG, WTRE, CIT
CLEVELAND BIOLABS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cleveland BioLabs, Inc. - CBLI
CLEVELAND BIOLABS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cleveland BioLabs, Inc. - CBLI
Cleveland BioLabs Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Cleveland BioLabs, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CBLI
Neutropenia Pipeline Monitor, 2020: Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook - ResearchAndMarkets.com
Cleveland BioLabs (NASDAQ:CBLI) Stock Price Down 9.8%
Cleveland BioLabs (NASDAQ:CBLI) Share Price Crosses Above Two Hundred Day Moving Average of $1.91